top of page

Abstract Line Pattern

Breast Cancer (HER2+)• Breast Cancer (HR+ / HER2-)• Breast Cancer (TNBC)

Join This Study

< Back

Breast Cancer (HER2+)• Breast Cancer (HR+ / HER2-)• Breast Cancer (TNBC)

(BRIA-ABC) Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Principal Investigator (PI)

Seneviratne, Lasika

Clinical Trials.gov ID

Key Eligibility

ClinicalTrails.gov

Protocol #

SPONSOR

BriaCell Therapeutics Corp.

bottom of page